Survodutide

Survodutide  is an investigational unimolecular dual agonist developed by Boehringer Ingelheim (licensed from Zealand Pharma) that activates both the glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR). Based on a modified glucagon backbone with C18 fatty acid acylation supporting once-weekly dosing, it is currently being evaluated in Phase 3 clinical trials (SYNCHRONIZE program) and represents an area of active incretin receptor research. This research-grade lyophilized powder is synthesized under strict quality controls and provided with full analytical documentation

• Research-grade peptide for laboratory and scientific use
• Produced to the highest purity and stability standards
• Lyophilized (freeze-dried) for optimal preservation
• Available in multiple quantities to support diverse research needs

We provide PEPTIDES of the highest purity and quality to ensure accuracy and reliability in scientific research.

Each product undergoes rigorous testing and quality control to meet the highest industry standards.

Quality & Formulation

Manufactured under strict quality control standards, the products are supplied in lyophilized powder form, ensuring:

    ✔ Enhanced stability during storage
    ✔ Consistent purity across batches
    ✔ Reliable reproducibility for laboratory research

By purchasing from Begin-Peptides, you agree to the following:

Research Use Only – All products are strictly for research purposes and are not intended for human, therapeutic, diagnostic or clinical use.

Not Medical Products – Our products are not medical items and must not be marketed, sold, or used as such.